{"id":634,"date":"2022-04-25T21:30:14","date_gmt":"2022-04-25T21:30:14","guid":{"rendered":"https:\/\/newsletters.aans.org\/tumor\/?page_id=634"},"modified":"2022-04-25T21:30:14","modified_gmt":"2022-04-25T21:30:14","slug":"report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022","status":"publish","type":"page","link":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/","title":{"rendered":"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022)"},"content":{"rendered":"<p>Alliance for Clinical Trials in Oncology:<\/p>\n<p>The clinical trial highlighted in this report is entitled \u201cPhase III trial of post-surgical single fraction stereotactic radiosurgery (SRS) compared with Fractionated SRS for Resected metastatic brain disease.\u201d SRS is commonly used as adjuvant therapy after surgery for brain metastasis, however the ideal number of fractions remains unclear. The primary outcome is comparison of local control between the two adjuvant radiation techniques (single fraction vs 3-5 fractions) up to 2 years after treatment. Target enrollment is 208 patients. Neurosurgeons who routinely see patients with brain metastases may be interested in this trial as it impacts treatment paradigms offered to patients. PI is Paul Brown, MD.<\/p>\n<p>Further information regarding this clinical trial can be obtained from the Alliance website at allianceforclinicaltrialsinoncology.org or clinicaltrials.gov.\u00a0 A list of ongoing trials sponsored by the Alliance can be accessed via the Alliance website.<\/p>\n<p>The spring Alliance for Clinical Trials in Oncology meeting is a hybrid in person\/virtual meeting Saturday, May 14, 2022 in Chicago, IL.<\/p>\n<p>&nbsp;<\/p>\n<p>J. Bradley Elder, MD<\/p>\n<p>Liaison to Alliance for Clinical Trials in Oncology<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alliance for Clinical Trials in Oncology: The clinical trial highlighted in this report is entitled \u201cPhase III trial of post-surgical single fraction stereotactic radiosurgery (SRS) compared with Fractionated SRS for Resected metastatic brain disease.\u201d SRS is commonly used as adjuvant therapy after surgery for brain metastasis, however the ideal number of fractions remains unclear. The [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":596,"menu_order":8,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-634","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022) - Tumor News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022) - Tumor News\" \/>\n<meta property=\"og:description\" content=\"Alliance for Clinical Trials in Oncology: The clinical trial highlighted in this report is entitled \u201cPhase III trial of post-surgical single fraction stereotactic radiosurgery (SRS) compared with Fractionated SRS for Resected metastatic brain disease.\u201d SRS is commonly used as adjuvant therapy after surgery for brain metastasis, however the ideal number of fractions remains unclear. The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Tumor News\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-news-spring-2022\\\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-news-spring-2022\\\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\\\/\",\"name\":\"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022) - Tumor News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\"},\"datePublished\":\"2022-04-25T21:30:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-news-spring-2022\\\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-news-spring-2022\\\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-news-spring-2022\\\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tumor News Spring 2022\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/tumor-news-spring-2022\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"name\":\"Tumor News\",\"description\":\"Just another AANS Newsletter Sites site\",\"publisher\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\",\"name\":\"Tumor News\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"contentUrl\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"width\":2336,\"height\":2294,\"caption\":\"Tumor News\"},\"image\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022) - Tumor News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/","og_locale":"en_US","og_type":"article","og_title":"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022) - Tumor News","og_description":"Alliance for Clinical Trials in Oncology: The clinical trial highlighted in this report is entitled \u201cPhase III trial of post-surgical single fraction stereotactic radiosurgery (SRS) compared with Fractionated SRS for Resected metastatic brain disease.\u201d SRS is commonly used as adjuvant therapy after surgery for brain metastasis, however the ideal number of fractions remains unclear. The [&hellip;]","og_url":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/","og_site_name":"Tumor News","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/","url":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/","name":"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022) - Tumor News","isPartOf":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#website"},"datePublished":"2022-04-25T21:30:14+00:00","breadcrumb":{"@id":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/report-from-the-alliance-for-clinical-trials-in-neuro-oncology-april-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/newsletters.aans.org\/tumor\/"},{"@type":"ListItem","position":2,"name":"Tumor News Spring 2022","item":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2022\/"},{"@type":"ListItem","position":3,"name":"Report from the Alliance for Clinical Trials in Neuro-Oncology (April, 2022)"}]},{"@type":"WebSite","@id":"https:\/\/newsletters.aans.org\/tumor\/#website","url":"https:\/\/newsletters.aans.org\/tumor\/","name":"Tumor News","description":"Just another AANS Newsletter Sites site","publisher":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/newsletters.aans.org\/tumor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/newsletters.aans.org\/tumor\/#organization","name":"Tumor News","url":"https:\/\/newsletters.aans.org\/tumor\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/","url":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","contentUrl":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","width":2336,"height":2294,"caption":"Tumor News"},"image":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/comments?post=634"}],"version-history":[{"count":3,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/634\/revisions"}],"predecessor-version":[{"id":637,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/634\/revisions\/637"}],"up":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/596"}],"wp:attachment":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/media?parent=634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}